| Literature DB >> 35425531 |
Yufei Ma1, Yulian Tao1, Hanyang Qu1, Cuihong Wang2, Fei Yan1, Xiujun Gao1, Meiling Zhang1.
Abstract
Recent outbreaks of coronavirus have brought serious challenges to public health around the world, and it is essential to find effective treatments. In this study, the 3C-like proteinase (3CLpro) of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has been considered as an important drug target because of its role in viral replication. We initially optimized 251 compounds at the PM7 level of theory for docking with 3CLpro, and then we selected the top 12 compounds for further optimization with the B3LYP-D3/6-311G** method and obtained the top four compounds by further molecular docking. Quantum chemistry calculations were performed to predict molecular properties, such as the electrostatic potential and some CDFT descriptors. We also performed molecular dynamics simulations and free energy calculations to determine the relative stability of the selected four potential compounds. We have identified key residues controlling the 3CLpro/ligand binding from per-residue based decomposition of the binding free energy. Convincingly, the comprehensive results support the conclusion that the compounds have the potential to become a candidate for anti-coronavirus treatment. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35425531 PMCID: PMC8981245 DOI: 10.1039/d1ra07364h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1The 3D model shows the main residues that are part of the active site of the Mpro.
Fig. 2The flow chart of screening anti-coronavirus compounds from the small molecule library and the methods of studying the properties of the screened molecules.
Fig. 3The 3D and 2D interaction diagram of SARS-CoV-2 Mpro with four compounds: (a) neocryptomerin, (b) isocryptomerin, (c) hinokiflavone, (d) amentoflavone.
Binding residues of top 12 compounds at 4 Å area in the active pocket of SARS-CoV-2 Mpro
| S. no. | Compounds | Binding energy (kcal mol−1) | Interacting residues |
|---|---|---|---|
| 1 | Isocryptomerin | −9.7 | Ala191, Glu166, Gln192, Pro168Thr190, Gln189, Leu167, Arg188, Mer165, Asp187, His41, Met49, His164, Cys145, Leu27, Thr25, Ser46, Thr45, Thr24, Thr26 |
| 2 | Hinokiflavone | −9.7 | Pro168, Gln192, Thr190, Ala191Gln189, Arg188, Met165, Asp187, His164, Met49, Thr26, Thr24, Thr45, Ser46, Thr25, Leu27, Gly143, Cys145, Asn142, His41, Glu166, Leu167 |
| 3 | Amentoflavone | −9.5 | Asn142, Ser46, Thr26, His41, Met165, Arg188, Asp187, Tyr54, His164, Cys145, Gly143, Thr24, Thr25, Met49, Pro168, Glu166, Gln189 |
| 4 | Neocryptomerin | −9.5 | Cys145, Ser46, Thr24, Met165, Met49, His41, Thr25, Ala191, Arg188, Pro168, Gln189, Thr190, Gln192, Leu167, Glu166, Asn142, Thr45, Thr26, Leu27, His164, Asp187 |
| 5 | Robustaflavone | −9.3 | Leu141, Gly143, Ser144, Cys145, Asn142, Thr25, Thr26, Leu27, His163, Phe140, His172, His164, His41, Leu167, Met165, Glu166, Gln189, Pro168, Thr190, Gln192, Ala191 |
| 6 | Podocarpusflavone A | −9.3 | Met49, His41, Cys145, His164, Gln189, Met165, Arg188, Leu167, Thr190, Ala191, Gln192, Pro168, His163, Glu166, His172, Asn142, Leu141, Phe140, Ser144 |
| 7 | Cupressiflavone | −9.3 | Asp197, Arg131, Lys137, Thr198, Asn238, Thr199, Leu289, Asp289, Leu287, Tyr239, Leu272, Tyr237 |
| 8 | Isoginkgetin | −9.2 | Asn142, Phe140, Ser144, Leu141, His163, Cys143, Glu166, Gln189, His164, His41, Met165, Arg188, Met49, Leu167, Gln192, Asp187, Thr190, Pro168, Ala191 |
| 9 | Podocarpusflavone B | −9.1 | Thr25, Ser46, Met49, Leu141, Leu27, Gly143, Asn142, Ser144, Cys145, Phe140, Gln189, Glu166, His163, His172, His164, His41, Met165, Asp187, Tyr54, Arg188 |
| 10 | Procyanidin A2 | −9.0 | Leu167, Glu166, Pro168, Met165, Gln189, Agr188, Asp187, His41, His163, His172, Phe140, Asn142, Cys145, Met49, Ser144, Thr25, Gly143, Thr26, Leu27, His164 |
| 11 | Robustaflavone | −8.9 | Leu141, Gly143, Asn142, Thr25, Thr26, Cys145, His163, Leu27, His164, His41, Phe140, His172, Glu166, Met165, Leu167, Gln189, GPro168, Thr190, Gln192, Ala191 |
| 12 | Sesguoiafiavone | −8.6 | Thr26, Thr25, Met49, Gly143, Ser46, Asn142, Cys145, His41, His164, Glu166, Met165, Asp187, Glu189, Arg188, Tyr54 |
Fig. 4ESP mapped molecular vdW surface of the selected compounds and the area percentage in each ESP range: (a) neocryptomerin, (b) isocryptomerin, (c) hinokiflavone and (d) amentoflavone.
The Conceptual Density Functional Theory (CDFT) using DFT calculated at B3LYP-D3/6-311G**
| CDFT descriptors | Neocryptomerin | Hinokiflavone | Isocryptomerin | Amentoflavone |
|---|---|---|---|---|
| E_HOMO (eV) | −6.16 | −6.14 | −6.18 | −6.02 |
| E_LUMO (eV) | −1.76 | −1.76 | −1.78 | −2.08 |
| Ionization potential (eV) | 6.16 | 6.14 | 6.18 | 6.02 |
| Electron affinity (eV) | 1.76 | 1.76 | 1.78 | 2.08 |
| Energy gap (eV) | 4.40 | 4.38 | 4.40 | 3.94 |
| Mulliken electronegativity (eV) | 3.96 | 3.95 | 3.98 | 4.05 |
| Chemical potential (eV) | −3.96 | −3.95 | −3.98 | −4.05 |
| Hardness (eV) | 6.47 | 6.46 | 6.48 | 6.43 |
| Softness (eV − 1) = 1/hardness | 0.15 | 0.15 | 0.15 | 0.16 |
| Electrophilicity index (eV) | 1.21 | 1.21 | 1.22 | 1.28 |
| Nucleophilicity index (eV) | 2.97 | 2.98 | 2.94 | 3.10 |
Fig. 5Frontier molecular orbitals for (a) neocryptomerin, (b) isocryptomerin, (c) hinokiflavone, and (d) amentoflavone inhibitor.
Fig. 6Root-mean-square deviation (RMSD) of the backbone atoms from the initial structure for four compounds (a–d) towards the SARS-CoV-2 main protease (Mpro) over 100 ns MD simulations.
Fig. 7Energy components (kcal mol−1) for the binding of four compounds to 3CLpro receptor, including van der Waals interaction (ΔEvdW), electrostatic interaction (ΔEele), polar solvation energy (ΔGpol), non-polar solvation energy (ΔGnp), and estimated binding affinity (ΔGbind).
Energetic components of the binding free energy (kcal mol−1) for SARS-CoV-2-inhibitor complexes calculated using MM-PBSA
| Components | Neocryptomerin | Isocryptomerin | Hinokiflavone | Amentoflavone |
|---|---|---|---|---|
| Δ | −37.62 | −7.66 | −41.06 | −44.08 |
| Δ | 0.35 | −3.33 | −8.45 | −16.36 |
| Δ | 27.91 | 12.12 | 32.90 | 43.96 |
| Δ | −3.71 | −0.82 | −3.90 | −4.079 |
| Δ | −13.10 | 0.30 | −20.50 | −20.56 |
Fig. 8Decomposition of the binding free energy into contributions from individual residues for 3CLpro complexed with neocryptomerin, isocryptomerin, hinokiflavone and amentoflavone.